CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
5.64
1.07%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.07
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

TELA Bio Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 5.59
Open* 5.53
1-Year Change* -46.62%
Day's Range* 5.53 - 5.72
52 wk Range 4.23-12.32
Average Volume (10 days) 168.16K
Average Volume (3 months) 3.47M
Market Cap 170.20M
P/E Ratio -100.00K
Shares Outstanding 24.49M
Revenue 53.08M
EPS -2.06
Dividend (Yield %) N/A
Beta 0.98
Next Earnings Date Mar 19, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 27, 2024 5.59 0.16 2.95% 5.43 5.61 5.43
Mar 26, 2024 5.53 0.17 3.17% 5.36 5.64 5.35
Mar 25, 2024 5.42 -0.29 -5.08% 5.71 5.81 5.30
Mar 22, 2024 5.68 0.09 1.61% 5.59 5.98 5.48
Mar 21, 2024 5.29 -0.09 -1.67% 5.38 5.76 5.28
Mar 20, 2024 5.47 0.29 5.60% 5.18 5.52 5.18
Mar 19, 2024 5.32 0.07 1.33% 5.25 5.44 5.20
Mar 18, 2024 5.29 -0.01 -0.19% 5.30 5.47 5.10
Mar 15, 2024 5.31 0.08 1.53% 5.23 5.47 5.20
Mar 14, 2024 5.39 -0.11 -2.00% 5.50 5.50 5.24
Mar 13, 2024 5.51 0.22 4.16% 5.29 5.52 5.28
Mar 12, 2024 5.35 -0.12 -2.19% 5.47 5.48 5.33
Mar 11, 2024 5.50 -0.18 -3.17% 5.68 5.78 5.32
Mar 8, 2024 5.72 -0.33 -5.45% 6.05 6.28 5.70
Mar 7, 2024 6.22 -0.02 -0.32% 6.24 6.36 6.20
Mar 6, 2024 6.37 -0.11 -1.70% 6.48 6.57 6.24
Mar 5, 2024 6.62 -0.13 -1.93% 6.75 6.79 6.48
Mar 4, 2024 6.87 -0.10 -1.43% 6.97 7.15 6.79
Mar 1, 2024 7.06 0.54 8.28% 6.52 7.14 6.49
Feb 29, 2024 6.74 0.21 3.22% 6.53 6.79 6.53

TELA Bio, Inc. Events

Time (UTC) Country Event
Friday, May 31, 2024

Time (UTC)

14:00

Country

US

Event

TELA Bio Inc Annual Shareholders Meeting
TELA Bio Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 41.418 29.463 18.213 15.446 8.274
Revenue 41.418 29.463 18.213 15.446 8.274
Cost of Revenue, Total 14.374 10.65 6.979 6.174 5.332
Gross Profit 27.044 18.813 11.234 9.272 2.942
Total Operating Expense 81.653 58.914 43.488 34.608 27.878
Selling/General/Admin. Expenses, Total 57.114 41.521 32.254 24.283 18.545
Research & Development 8.937 6.743 4.255 4.151 4.339
Unusual Expense (Income) 1.228 0 -0.338
Operating Income -40.235 -29.451 -25.275 -19.162 -19.604
Interest Income (Expense), Net Non-Operating -4.051 -3.597 -3.564 -3.609 -1.802
Other, Net -0.01 -0.228 0.045 0.346 0.314
Net Income Before Taxes -44.296 -33.276 -28.794 -22.425 -21.092
Net Income After Taxes -44.296 -33.276 -28.794 -22.425 -21.092
Net Income Before Extra. Items -44.296 -33.276 -28.794 -22.425 -21.092
Net Income -44.296 -33.276 -28.794 -22.425 -21.092
Total Adjustments to Net Income 0 -7.783 -8.823
Income Available to Common Excl. Extra. Items -44.296 -33.276 -28.794 -30.208 -29.915
Income Available to Common Incl. Extra. Items -44.296 -33.276 -28.794 -30.208 -29.915
Diluted Net Income -44.296 -33.276 -28.794 -30.208 -29.915
Diluted Weighted Average Shares 16.2677 14.4732 12.9344 11.4062 11.0068
Diluted EPS Excluding Extraordinary Items -2.72295 -2.29914 -2.22615 -2.64838 -2.71788
Dividends per Share - Common Stock Primary Issue 0
Diluted Normalized EPS -2.64746 -2.29914 -2.22615 -2.64838 -2.74858
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 14.494 11.909 11.622 11.159 10.406
Revenue 14.494 11.909 11.622 11.159 10.406
Cost of Revenue, Total 4.293 4.011 3.446 3.84 3.856
Gross Profit 10.201 7.898 8.176 7.319 6.55
Total Operating Expense 24.856 23.163 21.061 20.646 21.871
Selling/General/Admin. Expenses, Total 18.049 17.1 14.889 14.704 14.685
Research & Development 2.514 2.052 2.726 2.102 2.102
Operating Income -10.362 -11.254 -9.439 -9.487 -11.465
Interest Income (Expense), Net Non-Operating -1.298 -1.246 -1.174 -1.032 -0.934
Other, Net 0.87 0.473 0.634 -0.195 -0.342
Net Income Before Taxes -10.79 -12.027 -9.979 -10.714 -12.741
Net Income After Taxes -10.79 -12.027 -9.979 -10.714 -12.741
Net Income Before Extra. Items -10.79 -12.027 -9.979 -10.714 -12.741
Net Income -10.79 -12.027 -9.979 -10.714 -12.741
Income Available to Common Excl. Extra. Items -10.79 -12.027 -9.979 -10.714 -12.741
Income Available to Common Incl. Extra. Items -10.79 -12.027 -9.979 -10.714 -12.741
Diluted Net Income -10.79 -12.027 -9.979 -10.714 -12.741
Diluted Weighted Average Shares 23.2393 19.1856 19.1914 16.7586 14.5575
Diluted EPS Excluding Extraordinary Items -0.4643 -0.62688 -0.51997 -0.63931 -0.87522
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.4643 -0.62688 -0.51997 -0.63931 -0.79087
Unusual Expense (Income) 0 0 0 1.228
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 62.447 59.055 83.225 64.334 23.254
Cash and Short Term Investments 42.019 43.931 74.394 54.587 17.278
Cash & Equivalents 42.019 43.931 74.394 45.302 17.278
Total Receivables, Net 6.621 4.234 2.683 2.836 1.298
Accounts Receivable - Trade, Net 6.621 4.234 2.683 2.836 1.298
Total Inventory 11.792 7.658 3.907 4.603 4.348
Prepaid Expenses 2.015 3.232 2.241 2.308 0.33
Total Assets 67.855 62.544 86.458 67.922 27.227
Property/Plant/Equipment, Total - Net 2.909 1.186 0.626 0.677 0.758
Property/Plant/Equipment, Total - Gross 7.049 4.943 4.359 4.198 4.001
Accumulated Depreciation, Total -4.14 -3.757 -3.733 -3.521 -3.243
Intangibles, Net 2.499 2.303 2.607 2.911 3.215
Other Long Term Assets, Total 0
Total Current Liabilities 12.403 10.575 6.605 6.713 9.559
Accounts Payable 1.534 2.414 0.652 3.171 3.421
Accrued Expenses 10.869 8.161 5.953 3.533 5.153
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0
Other Current Liabilities, Total 0.009 0.985
Total Liabilities 53.55 42.446 37.432 36.96 40.937
Total Long Term Debt 39.916 31.491 30.827 30.243 31.373
Long Term Debt 39.916 31.491 30.827 30.243 31.373
Other Liabilities, Total 1.231 0.38 0.004 0.005
Total Equity 14.305 20.098 49.026 30.962 -13.71
Redeemable Preferred Stock 0 0 0 124.15
Common Stock 0.019 0.015 0.014 0.011 0
Retained Earnings (Accumulated Deficit) -274.225 -229.929 -196.653 -167.859 -137.86
Total Liabilities & Shareholders’ Equity 67.855 62.544 86.458 67.922 27.227
Total Common Shares Outstanding 19.165 14.5296 14.4371 11.4062 11.0068
Short Term Investments 0 9.285
Additional Paid-In Capital 288.361 250.064 245.736 198.829
Other Equity, Total 0.15 -0.052 -0.071 -0.019
Total Preferred Shares Outstanding 0
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 82.252 89.168 53.502 62.447 73.955
Cash and Short Term Investments 58.202 65.266 30.124 42.019 54.226
Cash & Equivalents 58.202 65.266 30.124 42.019 54.226
Total Receivables, Net 8.072 7.894 6.654 6.621 5.688
Accounts Receivable - Trade, Net 8.072 7.894 6.654 6.621 5.688
Total Inventory 14.323 14.098 15.105 11.792 12.138
Prepaid Expenses 1.655 1.91 1.619 2.015 1.903
Total Assets 87.317 94.386 58.788 67.855 79.563
Property/Plant/Equipment, Total - Net 2.851 2.909 2.882 2.909 3.014
Intangibles, Net 2.214 2.309 2.404 2.499 2.594
Total Current Liabilities 15.334 13.045 14.406 12.403 15.214
Accounts Payable 3.091 2.25 5.216 1.534 4.856
Accrued Expenses 12.243 10.795 9.19 10.869 10.358
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 56.765 54.381 55.647 53.55 56.262
Total Long Term Debt 40.363 40.212 40.063 39.916 39.766
Long Term Debt 40.363 40.212 40.063 39.916 39.766
Other Liabilities, Total 1.068 1.124 1.178 1.231 1.282
Total Equity 30.552 40.005 3.141 14.305 23.301
Redeemable Preferred Stock 0 0 0 0
Common Stock 0.024 0.024 0.019 0.019 0.019
Additional Paid-In Capital 338.392 336.939 289.254 288.361 287.266
Retained Earnings (Accumulated Deficit) -307.999 -297.042 -286.252 -274.225 -264.246
Other Equity, Total 0.135 0.084 0.12 0.15 0.262
Total Liabilities & Shareholders’ Equity 87.317 94.386 58.788 67.855 79.563
Total Common Shares Outstanding 24.4876 24.4755 19.2278 19.165 19.1591
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -44.296 -33.276 -28.794 -22.425 -21.092
Cash From Operating Activities -40.748 -30.432 -24.456 -25.523 -19.924
Cash From Operating Activities 0.383 0.231 0.221 0.278 0.463
Amortization 0.804 0.304 0.304 0.304 0.785
Non-Cash Items 7.74 5.766 3.969 2.576 4.375
Cash Interest Paid 3.394 2.933 2.98 3.086 1.09
Changes in Working Capital -5.379 -3.457 -0.156 -6.256 -4.455
Cash From Investing Activities -1.872 -0.627 9.122 -11.981 -1.558
Capital Expenditures -1.872 -0.627 -0.167 -2.697 -1.562
Other Investing Cash Flow Items, Total 0 0 9.289 -9.284 0.004
Cash From Financing Activities 40.852 0.585 44.409 65.532 27.414
Financing Cash Flow Items -3.617 0 -0.522 0 -1.569
Issuance (Retirement) of Stock, Net 34.469 0.585 44.931 65.532 3.983
Issuance (Retirement) of Debt, Net 10 0 0 25
Net Change in Cash -1.912 -30.463 29.092 28.024 5.932
Foreign Exchange Effects -0.144 0.011 0.017 -0.004
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -12.027 -44.296 -34.317 -23.603 -10.862
Cash From Operating Activities -11.574 -40.748 -29.765 -22.116 -10.43
Cash From Operating Activities 0.12 0.383 0.271 0.161 0.078
Amortization 0.095 0.804 0.709 0.614 0.076
Non-Cash Items 1.851 7.74 6.494 4.703 1.924
Cash Interest Paid 1.099 3.394 2.37 1.486 0.733
Changes in Working Capital -1.613 -5.379 -2.922 -3.991 -1.646
Cash From Investing Activities -0.115 -1.872 -0.826 -0.536 -0.336
Capital Expenditures -0.115 -1.872 -0.826 -0.536 -0.336
Other Investing Cash Flow Items, Total 0
Cash From Financing Activities -0.235 40.852 41.071 6.502 -0.146
Financing Cash Flow Items -0.279 -3.617 -3.617 -3.51 -0.153
Issuance (Retirement) of Stock, Net 0.044 34.469 34.688 0.012 0.007
Foreign Exchange Effects 0.029 -0.144 -0.185 -0.056 -0.003
Net Change in Cash -11.895 -1.912 10.295 -16.206 -10.915
Issuance (Retirement) of Debt, Net 10 10 10

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

TELA Bio, Inc. Company profile

About TELA Bio Inc

TELA Bio Inc. is a medical technology company. The Company is focused on designing, developing and marketing tissue reinforcement materials for soft tissue reconstruction. It offers a portfolio of products and solutions for care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. Its portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), is used for ventral hernia repair and abdominal wall reconstruction, inguinal hernia repair and hiatal hernia repair. Its OviTex PRS Reinforced Tissue Matrix (OviTex PRS) addresses needs in plastic and reconstructive surgery. Its OviTex PRS product is designed for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery. Its subsidiary include TELA Bio Limited.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, TELA Bio Inc revenues increased 62% to $29.5M. Net loss increased 16% to $33.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Other (expense) income decrease from $45K (income) to $228K (expense), Interest expense increase of 1% to $3.6M (expense).

Industry: Medical Equipment, Supplies & Distribution (NEC)

1 Great Valley Parkway, Suite 24
MALVERN
PENNSYLVANIA 19355
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

ETH/USD

3,561.25 Price
+1.380% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Gold

2,233.43 Price
+1.740% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.80

US100

18,249.40 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

XRP/USD

0.63 Price
+1.650% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading